Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Performance Evaluation of the VIDAS TB-IGRA Assay.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04048018
Recruitment Status : Not yet recruiting
First Posted : August 7, 2019
Last Update Posted : November 8, 2019
Sponsor:
Information provided by (Responsible Party):
BioMérieux

Brief Summary:
This study will evaluate the performance of the VIDAS® Interferon Gamma (IFN-γ) Release Assay (TB-IGRA) assay, which is intended for use as an aid in the diagnosis of tuberculosis infection. This study is designed to assess (1) the sensitivity of this assay, (2) its percent agreement with other diagnostic tests, (3) its measurement precision , and (4) any potential interference of the presence of other non-tuberculosis mycobacterial bacterial infections with this assay.

Condition or disease Intervention/treatment
Active Tuberculosis Latent Tuberculosis Infection Non-Tuberculous Mycobacterial (NTM) Pneumonia Diagnostic Test: Blood draw and IGRA test

Detailed Description:

Tuberculosis (TB) infection is one of the top 10 causes of death in the world and the leading cause of death due to a single infectious agent. Millions of people are infected with TB each year which can pose significant economic and health care burdens on the global population.

TB can infected the lungs (pulmonary TB) or other organs such as the brain, and kidneys (extra-pulmonary TB). When a person with pulmonary TB coughs or sneezes, water droplets containing M. tuberculosis are expelled into the air. Persons can become infected with TB when they inhale air containing these water droplets, however, not everyone infected with Mycobacterium tuberculosis (Mtb) becomes ill. Therefore two TB-related conditions exist: latent TB infection (LTBI) and TB disease.

People with latent TB infection are not ill and do not present TB symptoms or have TB disease. The only sign of TB infection is a positive reaction to the tuberculin skin test or TB blood tests such as IGRA tests. People with latent TB infection are not contagious and cannot spread TB infection to others.

Identification and treatment of LTBI can substantially reduce the risk of developing active disease. However, there is no diagnostic gold standard for LTBI. Two types of test are currently available for the identification of LTBI: the tuberculin skin test (TST) and the TB Interferon Gamma (IFN-γ) Release Assay (TB-IGRA). Evidence suggests that both TST and TB-IGRA are acceptable but not perfect because they detect indirect markers of Mtb exposure and indicate a cellular immune response to M. tuberculosis. TB-IGRAs have a number of advantages compared to TST which promote their progressive adoption in the clinical practice and in guidelines.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 2400 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Performance Evaluation of the VIDAS TB-IGRA Assay.
Estimated Study Start Date : December 5, 2019
Estimated Primary Completion Date : May 31, 2020
Estimated Study Completion Date : June 15, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tuberculosis

Group/Cohort Intervention/treatment
Active Tuberculosis Patient Diagnostic Test: Blood draw and IGRA test
One to two blood samples will be obtained from participants in all arms in order to conduct testing.

High risk for LTBI Participant Diagnostic Test: Blood draw and IGRA test
One to two blood samples will be obtained from participants in all arms in order to conduct testing.

Low risk for prior TB infection Participant Diagnostic Test: Blood draw and IGRA test
One to two blood samples will be obtained from participants in all arms in order to conduct testing.

NTM patient Diagnostic Test: Blood draw and IGRA test
One to two blood samples will be obtained from participants in all arms in order to conduct testing.

Precision patient Diagnostic Test: Blood draw and IGRA test
One to two blood samples will be obtained from participants in all arms in order to conduct testing.




Primary Outcome Measures :
  1. Positive, negative, indeterminate for tuberculosis [ Time Frame: One-time measurement through study completion for each participant, an average of 5 months. ]
    The VIDAS or comparator assays will qualitatively determine the presence or absence of Mycobacterial TB infection in a participant's blood. This measurement is based on the level of interferon gamma released after stimulation of T cells in blood.

  2. Sensitivity and positive and negative percent agreement for the VIDAS TB IGRA assay with comparator assay [ Time Frame: One-time measurement through study completion for each participant, an average of 5 months. ]
    Results obtained using the VIDAS assay will be compared with the results obtained from other methods.

  3. Degree of Interference by nontuberculous mycobacteria for the VIDAS TB IGRA assay [ Time Frame: One-time measurement through study completion for each participant, an average of 5 months. ]
    Persons with NTM will be tested using the VIDAS TB IGRA.

  4. Measurement Precision of the VIDAS TB IGRA assay results [ Time Frame: Triplicate measurement per sample through study completion, an average of 5 months. ]
    6- 4mL blood samples will be collected from each participant and tested using different VIDAS instruments.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
This study will enroll persons with low to high risk factors for acquiring TB infection, persons with active TB disease, and persons with other types of Mycobacterial infections
Criteria

Active TB Population

Inclusion Criteria:

A person classified as or suspected of having M. tuberculosis disease (active TB):

A person with known HIV status, determined by a laboratory or rapid test performed no earlier than one month prior to, or at the time of inclusion into this study A person of age ≥ 2 years

Exclusion Criteria:

A person who has been on an anti-TB treatment for >15 days for the ongoing infection Pregnant women A person who has received an anti-tumor necrosis factor (TNF) alpha treatment within the previous 3 months A person who has had prior TST A person with an NTM infection A person with positive HIV status.

High Risk for TB infection

Inclusion criteria :

A person who is at increased risk for M. tuberculosis infection (and therefore LTBI) and/or for progression to active TB:

A person with age ≥ 2 years A person with known HIV status

Non-inclusion criteria will be:

A person who has or has had active TB A person who has received treatment for active TB or LTBI A person who has received an anti-TNF alpha treatment A person who has had a TST Pregnant women Person who has been an NTM infection

Low Risk for TB Infection

Inclusion criteria

Generally healthy people, unlikely to have encountered TB disease in the past, that may be subject to TB testing for professional, academic or personal reasons (e.g.: students, healthcare personnel and healthcare volunteers, military recruits) A person with age ≥ 18 years old

Non-inclusion criteria A person who is considered at high risk for LTBI A person who has or has had active TB A person who has received treatment for active TB or LTBI A person who has received an anti-TNFalpha treatment A person who has had a TST Pregnant women A person who has been diagnosed with a NTM infection

NTM population:

Inclusion criteria A person who is positive for NTM of interest confirmed by culture and identification;

Non-inclusion criteria A person who has been on antibiotic treatment for NTM; A person with confirmed active TB; A person with HIV; A person with a history of active TB; A person who have received treatment for LTBI; A person who is at high risk for LTBI Pregnant women.

Precision Population

Inclusion criteria:

A person previously enrolled in the Active TB, High Risk or Low Risk studies, or a blood donor.

Non-inclusion criteria An adult who was not previously enrolled in the Active TB, High Risk or Low Risk studies except for blood donors

For blood donors only:

A person who can be classified as being at increased risk for M. tuberculosis infection (and therefore LTBI) and/or for progression to active TB


Layout table for additonal information
Responsible Party: BioMérieux
ClinicalTrials.gov Identifier: NCT04048018    
Other Study ID Numbers: B2694-CTPR
First Posted: August 7, 2019    Key Record Dates
Last Update Posted: November 8, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Product Manufactured in and Exported from the U.S.: No
Keywords provided by BioMérieux:
Interferon Gamma Release Assay
Tuberculosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Tuberculosis
Latent Tuberculosis
Pneumonia
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections